NEW YORK, Nov. 18, 2015 /PRNewswire/ -- Testing for infectious diseases is one of the largest parts of the global IVD testing and represent a 16.8 billion-dollar market, according to Kalorama Information. The healthcare market research firm said that the segment benefits from demands and growing infrastructure in emerging nations, as well as intense competition. The finding was made in Kalorama Information's report, The World Market for Infectious Disease Testing.
"Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry," said Emil Salazar, IVD industry analyst and author of the report. "Occasional explosive market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures."
The report said that infectious diseases are also the frequent target of novel diagnostic technology applications including PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays, and mass spectrometry. Advancements in instrument automated analysis and microfluidics have allowed for the proliferation of infectious disease testing across settings and institutions – from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world. Conventional real-time PCR offers improved specificity and sensitivity to infectious disease testing regardless test setting and is playing a strong role in advanced therapeutics such as antiretroviral therapy. Infectious disease diagnostics also take on added importance beyond individual clinical cases in the surveillance and control of healthcare-threatening pathogens such as antimicrobial-resistant microorganisms.
"No one technology can satisfy clinical demand for infectious disease diagnostics," Salazar said.
Molecular tests can provide crucial genus- and species-specific information necessary in the investigation of epidemics and the study of antimicrobial resistance and other traits related to infection outbreaks. For the foreseeable future, laboratories will continue to rely upon traditional identification and antimicrobial sensitivity tests (ID/AST) and immunoassays for routine testing and molecular tests for hard-to-culture pathogens and the most time-critical infections.
The disparity in infectious disease test market growth rates is evident between industrialized, first-world countries with established healthcare systems in North America, Europe and Asia (Japan) and countries of the developing world, according to the report. The developed world is projected to be held to an under-4% aver annual growth rate in terms of infectious disease test sales through 2020. Countries such as China, India and in Latin America, on the other hand, remain in the process of implementing rapid testing as part of infectious disease screening and molecular assays for the diagnosis and treatment of infectious diseases.
"Even established infectious disease testing tools such as culture ID/AST can expect more robust rates of growth in the developing world as labs update their microbiology testing to automated platforms and increase capacity to handle increased patient volume," Salazar said.
For more information, Kalorama's complete study of the market, The World Market for Infectious Disease Tests is available at their website at: http://www.kaloramainformation.com/redirect.asp?progid=88016&productid=9367616.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
SOURCE Kalorama Information